Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis

TOSHIKI MASUISHI, SHIGENORI KADOWAKI, MAYUMI KONDO, AZUSA KOMORI, KEIJI SUGIYAMA, SEIICHIRO MITANI, KAZUNORI HONDA, YUKIYA NARITA, HIROYA TANIGUCHI, TAKASHI URA, MASASHI ANDO, HIDEYUKI MISHIMA and KEI MURO
Anticancer Research December 2017, 37 (12) 7037-7042;
TOSHIKI MASUISHI
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGENORI KADOWAKI
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: skadowaki@aichi-cc.jp
MAYUMI KONDO
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AZUSA KOMORI
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIJI SUGIYAMA
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEIICHIRO MITANI
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUNORI HONDA
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIYA NARITA
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYA TANIGUCHI
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI URA
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASASHI ANDO
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEYUKI MISHIMA
2Cancer Center, Aichi Medical University, Nagakute, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEI MURO
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Severe peritoneal metastasis (PM) from advanced gastric cancer (AGC) causes massive ascites and inadequate oral intake. Because patients with severe PM are often not included in clinical trials, little is known regarding the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil (FOLFOX) for them. Patients and Methods: We retrospectively studied AGC patients with massive ascites and/or inadequate oral intake due to severe PM treated with FOLFOX as the first-line treatment. Results: Only 39 (10%) of 378 AGC patients had severe PM; 10 received FOLFOX. The median progression-free and overall survivals were 7.5 and 13.2 months, respectively. Ascites decreased in seven of nine patients with ascites, and oral intake improved in four of seven patients with an inadequate oral intake. Common grade 3-4 adverse events included neutropenia and anemia. Conclusion: This study suggests that FOLFOX is effective and manageable for AGC patients with severe PM.

  • FOLFOX
  • advanced gastric cancer
  • peritoneal metastasis
  • massive ascites
  • inadequate oral intake
  • Received September 10, 2017.
  • Revision received September 27, 2017.
  • Accepted September 28, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (12)
Anticancer Research
Vol. 37, Issue 12
December 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis
TOSHIKI MASUISHI, SHIGENORI KADOWAKI, MAYUMI KONDO, AZUSA KOMORI, KEIJI SUGIYAMA, SEIICHIRO MITANI, KAZUNORI HONDA, YUKIYA NARITA, HIROYA TANIGUCHI, TAKASHI URA, MASASHI ANDO, HIDEYUKI MISHIMA, KEI MURO
Anticancer Research Dec 2017, 37 (12) 7037-7042;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis
TOSHIKI MASUISHI, SHIGENORI KADOWAKI, MAYUMI KONDO, AZUSA KOMORI, KEIJI SUGIYAMA, SEIICHIRO MITANI, KAZUNORI HONDA, YUKIYA NARITA, HIROYA TANIGUCHI, TAKASHI URA, MASASHI ANDO, HIDEYUKI MISHIMA, KEI MURO
Anticancer Research Dec 2017, 37 (12) 7037-7042;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Nivolumab Plus 5-Fluorouracil/Leucovorin+Oxaliplatin for Gastric Cancer With Severe Peritoneal Metastasis
  • Efficacy and Safety of FOLFOX in Advanced Gastric Cancer Initially Presenting With Disseminated Intravascular Coagulation
  • Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells
  • Gastric Cancer Cells in Peritoneal Lavage Fluid: A Systematic Review Comparing Cytological with Molecular Detection for Diagnosis of Peritoneal Metastases and Prediction of Peritoneal Recurrences
  • Google Scholar

More in this TOC Section

  • Palliative Radiotherapy for Large Osteolytic Metastatic Tumors Involving the Iliac Bone: A Report of 16 Cases
  • Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma
  • The Long-term Outcomes of Borderline Resectable T3 in Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Triplet Chemotherapy
Show more Clinical Studies

Similar Articles

Keywords

  • FOLFOX
  • advanced gastric cancer
  • peritoneal metastasis
  • massive ascites
  • inadequate oral intake
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire